File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of a Humanoid Companion Robot on Dementia Symptoms and Caregiver Distress for Residents in Long-Term Care

TitleEffects of a Humanoid Companion Robot on Dementia Symptoms and Caregiver Distress for Residents in Long-Term Care
Authors
KeywordsRandomized control trial
withdrawal ABAB design
psychosocial intervention
neuropsychiatric symptoms
Kabochan
Issue Date2020
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/jmda
Citation
Journal of the American Medical Directors Association, 2020, Epub 2020-07-23 How to Cite?
AbstractObjectives: To test the effects of deploying a humanoid companion robot (Kabochan) in comparison with usual care for long-term care facilities’ residents with dementia. Design: A 2-arm, randomized controlled trial with ABAB withdrawal design, lasting 32 weeks. After an 8-week baseline period, Kabochan was introduced in a nonfacilitated, individual approach with experimental-group participants (n = 52) for 8 weeks, then removed for 8 weeks, and then reintroduced for another 8 weeks. The control group (n = 51) received the usual standardized care. Setting and Participants: Seven long-term care facilities in Hong Kong. 103 residents (76% women, 87.2 ± 7.4 years) with a clinical diagnosis of dementia. Measures: Outcome assessments occurred at 5 time points: baseline (week 1) and the end of each phase (weeks 8, 16, 24, and 32). Primary outcomes were assessed with the Neuropsychiatric Inventory Questionnaire (symptom severity and caregiver distress subscales) and the Geriatric Depression Scale; secondary outcomes were measured by the Hong Kong Montreal Cognitive Assessment 5-minute Protocol, the Modified Barthel Index for Activities of Daily Living, and the Quality of Life–Alzheimer's disease scale. Results: A multivariate analysis of variance indicated a statistically significant group × time interaction for neuropsychiatric-related caregiver distress at week 16 (F = 6.72, P = .011), with a moderate effect size (η p 2 = 0.06). When Kabochan was removed in the withdrawal phase (weeks 17–24), the neuropsychiatric symptoms became more severe at week 24 for the intervention group (F = 4.68, P = .003), although the effect size was small to moderate (η p 2 = 0.04). No statistical between-group differences were found in other health outcomes. Conclusions and Implications: The Kabochan was potentially effective at reducing short-term neuropsychiatric symptoms and relevant caregiver distress for residents with dementia. An individualized care plan with continuous monitoring is required to integrate the humanoid robot into routine dementia care.
Persistent Identifierhttp://hdl.handle.net/10722/285028
ISSN
2019 Impact Factor: 4.367
2015 SCImago Journal Rankings: 1.551

 

DC FieldValueLanguage
dc.contributor.authorChen, K-
dc.contributor.authorLou, VWQ-
dc.contributor.authorTAN, KCK-
dc.contributor.authorWAI, MY-
dc.contributor.authorCHAN, LL-
dc.date.accessioned2020-08-07T09:05:47Z-
dc.date.available2020-08-07T09:05:47Z-
dc.date.issued2020-
dc.identifier.citationJournal of the American Medical Directors Association, 2020, Epub 2020-07-23-
dc.identifier.issn1525-8610-
dc.identifier.urihttp://hdl.handle.net/10722/285028-
dc.description.abstractObjectives: To test the effects of deploying a humanoid companion robot (Kabochan) in comparison with usual care for long-term care facilities’ residents with dementia. Design: A 2-arm, randomized controlled trial with ABAB withdrawal design, lasting 32 weeks. After an 8-week baseline period, Kabochan was introduced in a nonfacilitated, individual approach with experimental-group participants (n = 52) for 8 weeks, then removed for 8 weeks, and then reintroduced for another 8 weeks. The control group (n = 51) received the usual standardized care. Setting and Participants: Seven long-term care facilities in Hong Kong. 103 residents (76% women, 87.2 ± 7.4 years) with a clinical diagnosis of dementia. Measures: Outcome assessments occurred at 5 time points: baseline (week 1) and the end of each phase (weeks 8, 16, 24, and 32). Primary outcomes were assessed with the Neuropsychiatric Inventory Questionnaire (symptom severity and caregiver distress subscales) and the Geriatric Depression Scale; secondary outcomes were measured by the Hong Kong Montreal Cognitive Assessment 5-minute Protocol, the Modified Barthel Index for Activities of Daily Living, and the Quality of Life–Alzheimer's disease scale. Results: A multivariate analysis of variance indicated a statistically significant group × time interaction for neuropsychiatric-related caregiver distress at week 16 (F = 6.72, P = .011), with a moderate effect size (η p 2 = 0.06). When Kabochan was removed in the withdrawal phase (weeks 17–24), the neuropsychiatric symptoms became more severe at week 24 for the intervention group (F = 4.68, P = .003), although the effect size was small to moderate (η p 2 = 0.04). No statistical between-group differences were found in other health outcomes. Conclusions and Implications: The Kabochan was potentially effective at reducing short-term neuropsychiatric symptoms and relevant caregiver distress for residents with dementia. An individualized care plan with continuous monitoring is required to integrate the humanoid robot into routine dementia care.-
dc.languageeng-
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/jmda-
dc.relation.ispartofJournal of the American Medical Directors Association-
dc.subjectRandomized control trial-
dc.subjectwithdrawal ABAB design-
dc.subjectpsychosocial intervention-
dc.subjectneuropsychiatric symptoms-
dc.subjectKabochan-
dc.titleEffects of a Humanoid Companion Robot on Dementia Symptoms and Caregiver Distress for Residents in Long-Term Care-
dc.typeArticle-
dc.identifier.emailChen, K: kechen@hku.hk-
dc.identifier.emailLou, VWQ: wlou@hku.hk-
dc.identifier.authorityLou, VWQ=rp00607-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jamda.2020.05.036-
dc.identifier.pmid32713772-
dc.identifier.scopuseid_2-s2.0-85088379652-
dc.identifier.hkuros312622-
dc.identifier.volumeEpub 2020-07-23-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats